Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Affiliation

State Key Laboratory of Oncology in South China, Sun Yat-sen University, Guangzhou 510060, China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University, Guangzhou 510060, China; Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Sun Yat-sen University, Guangzhou 510060, China; Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou 510060, China. Electronic address: [Email]

Abstract

Compared with conventional fluorouracil plus cisplatin (FP) regimen, gemcitabine plus cisplatin (GP) can prolong survival in patients with recurrent or metastatic nasopharyngeal carcinoma, but the economic impact of this practice remains unknown. It's significant to evaluate its values by taking both efficacy and cost into consideration.

Keywords

Cisplatin,Cost-effectiveness,Fluorouracil,Gemcitabine,Nasopharyngeal carcinoma,Recurrent or metastatic,

OUR Recent Articles